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Living Donor Liver Transplantation 
Hesham Abdeldayem 
Professor of Surgery, National Liver Institute, Menoufeyia University, 
Egypt 
"As to diseases, make a habit of two things: to help, or at least, to do no harm." 
Hippocrates (460 - 377 BC) 
1. Introduction 
Living donor liver transplantation (LDLT) is probably the most high-profile of all surgical 
enterprises. At the same time, it is an amazing act of altruism. It requires hard work of 
dedicated multidisciplinary medical teams coupled with the courage of the patients and 
their families. The concept of LDLT is based on the following two factors: (1) the remarkable 
regenerative capacity of the liver, and (2) the shortage of cadaveric organs (Olthoff K, 2003). 
LDLT has become an acceptable alternative for patients in need of liver transplantation (LT) 
who are not likely to receive a deceased donor liver transplant (DDLT) in a timely fashion. 
This is seen especially in countries where cadaveric donation is limited by religious and 
cultural beliefs, as in Japan, Egypt, Korea, and India (Abdeldayem H, 2010). 
This chapter outlines the advantages and disadvantages of LDLT, addresses the moral and 
ethical issues surrounding this procedure, reviews the evaluation process of the recipient 
and the donor candidates, highlights controversial indication for LDLT, outlines technical 
aspects of LDLT, and the middle hepatic vein controversy and reviews donor and recipient 
outcomes and complications. Where possible, emphasis is placed on the differences in LDLT 
compared to whole organ DDLT. At the end, the author addresses the issue of living donor 
mortality and highlights the importance of transparency in LDLT.  
2. Historical perspective 
Liver transplantation utilizing a partial-liver graft was theoretically proposed for children 
by Smith in 1969. On 8 December 1988, Raia et al. made the first attempt at LDLT in a four 
and a half-year-old girl suffering from biliary atresia. In July 1989, Strong et al. performed 
the first LDLT with long-term success in an 11-month-old boy using segments II and III 
graft. Broelsch et al. soon followed with publication of the first series of 20 successful cases 
of LDLT in children at the University of Chicago (Broelsch et al.,1991).  
In 1991, Habib et al performed the first LDLT procedure in Africa and the Middle East at the 
National Liver Institute, in Egypt. They reported the success of their first case in 1993 (Habib 
et al, 1993). In the same year, Haberal et al. extended LDLT to adult recipients. In their 
series, they transplanted left-liver grafts to eight patients. In 1994, Yamaoka et al. reported 
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unplanned adult-to-child LDLT using right liver .In this particular case, the operative 
procedure was changed from left hepatectomy to right hepatectomy because of unfavorable 
anatomy of the left hepatic artery. 
3. Advantages and disadvantages  
In LDLT, the waiting time is reduced, with the ability to perform transplantation when it is 
medically indicated and the recipient is in the most optimal condition. This ensures better 
outcome before serious decompensation, disease progression (e.g., hepatocellular carcinoma) 
or death occurs (Russo M et al., 2004).  
LDLT is usually is scheduled on an elective basis, allowing time for completing 
pretransplant work-up of the recipient and donor. The entire surgical team is more rested 
since the surgery is planned electively. Extensive workup to exclude other diseases in the 
donor is made. Details of vascular and liver anatomy are known well before transplant. 
There will be an opportunity to treat, or at least control, viral hepatitis B or C infection prior 
to transplantation (in those who can tolerate the medication pretransplant). Bacteremia or 
sepsis, if present, can be cleared with appropriate antibiotic therapy prior to the procedure 
(Olthoff K, et al., 2005).  
Since the graft is transported between adjacent operating rooms, the cold ischemia time is 
short. The complications associated with organ preservation are minimized, and primary 
nonfunction is rare. Another advantage may be related to avoiding the activation of the 
inflammatory cascade seen in cadaveric livers obtained from brain dead donors, which has 
been implicated in up-regulation of inflammatory cytokines, adhesion molecules, class II 
presentation and in affecting microcirculatory flow to the, liver with resultant hepatocellular 
damage and allograft dysfunction. The age of the living donor is usually young. This avoids 
the usage of organs procured from terminally ill patient with the possibility of end-organ 
damage. (Jassem W et al., 2003) In LDLT, there is a potential for better human leukocyte 
antigen (HLA) matching. Improved matching may have an immunological advantage 
similar to that observed in living donor kidney transplantation. However, this was not 
proved (Neumann U et al., 2003). 
These advantages, though, need to be weighed against the fact that a healthy person is being 
exposed to an extensive abdominal surgery with its potential for morbidity and mortality. 
The incidence of biliary complications in the recipient are said to occur more frequently than 
in DDLT. LDLT recipients are also exposed to slightly higher risk of hepatic artery 
thrombosis. The so called “small-for-size syndrome”, may occur if careful size-matching 
between the donor and the recipient is not made. Additionally the donor has to face 
financial and emotional consequences. The donation will limit the functionality of the donor 
for weeks or months after the surgery (Abdeldayem H et al., 2009). 
4. Moral and ethical issues 
Primum non nocere "First do no harm”, a fundamental medical precept of Hippocrates, is 
an important philosophy believed in medicine. LDLT challenges this tenet, because a 
healthy individual undergoes a major operation for no physical benefit to himself or herself. 
Perhaps there is no greater ethical dilemma than to operate and remove an organ from a 
perfectly healthy individual to help another (Abdeldayem H et al., 2009). It seems that the  
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general public strongly believes that it is the donor’s sole right to donate an organ and this 
decision should rest with the donor. In liberal societies everyone has the right to participate 
in dangerous activities according to his or her will, but the transplant procedure involves an 
‘accomplice’; the transplant surgeon. Yet, for surgeons the principle according to the 
Hippocratic Oath is to ‘do no harm’. Does a surgeon have an obligation to remove a person’s 
organ upon request? (Mazaris E; Papalois V, 2006) 
4.1 Donor’s motivation 
It is important that donors feel they are gaining something by donation so as to be 
sufficiently motivated and that their profit is of an emotional or moral nature (Sauer P et 
al., 2004). Donor motivation may be influenced by the type of relationship to the recipient 
and personal and religious beliefs and values. Donor motivations may include, a desire to 
help, a feeling of moral duty, a perception that donation is something that he or she is 
expected to do, and an increase in self-esteem from doing good deeds. Donors may 
imagine themselves in the recipient’s situation, especially siblings, who are sure that the 
latter would act accordingly if they were in a similar state. That may be the case for 
parents as well. Spouses may be motivated by self-benefit from their companion’s 
improved health and the improvement of the couple’s quality of life (Lennerling A, et al, 
2004). The reasons for donation must be thoroughly explored by the team and the donor. 
The social worker must assess whether the volunteer’s decision is made freely without 
any undo pressure or coercion, and whether motivation is consistent with the donor’s 
values and previous behaviors. Pressure may be more likely when the recipient’s death is 
imminent without a transplant and when no other donor options exist (Lennerling A, et 
al, 2004).  
4.2 Informed consent 
Individuals considering living donation must be free to decide how much and what sort of 
risk is acceptable for them. Potential donors cannot make such decisions if they are not first 
provided with proper informed consent regarding the risks they are undertaking and 
potential implications their decision may have on the recipient. The person who consents 
to be a live donor should be competent, willing to donate, free from coercion, medically 
and psychosocially suitable, fully informed of the risks, benefits and alternative treatment 
available to the recipient. The professional who provides informed consent for donation 
should be a neutral third person. A transplant centre may have reasons for wanting an 
organ donation to go ahead: transplants are their source of income; they are able to 
increase their prestige and conduct research (Abdeldayem H. et al., 2009; Steiner R & Gert 
B 2000).  
Issues to be fully explained to the potential donor include: 
1. The technical elements of the evaluation process, surgery and recovery, short- and long-
term follow-up care. 
2. The risk for complications and death to both the donor and the recipient.  
3. Medical uncertainties, including the potential for long-term donor complications.  
4. Unforeseeable consequences that might change the donor’s life, e.g. employment, and 
insurability, and expenses to be borne by the donor.  
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5. Expected outcome of transplantation for the recipient. 
6. Any alternative therapies available to the recipient.  
7. The specific experience and statistics of the transplant centre. 
4.2.1 Informed understanding 
The donor must demonstrate informed understanding. This is best achieved with written 
and verbal presentation of the necessary information in lay language and in accordance with 
the person’s educational level. The potential donor must demonstrate their understanding 
of the essential elements of the donation process, particularly the risks of the procedure. 
Adequate time should be allowed for the potential donor to absorb the information, and ask 
questions. This may require several consultations. The donor’s family/ loved ones are given 
the opportunity to discuss their concerns (Trotter J et al., 2007). The donor should be given a 
period of time to review the decision to donate (Abdullah K et al, 2005). It is very important 
to inform the prospective donor that he or she can choose not to proceed with the surgery 
without the risks of coercion or consequences. If the donor is not accepted, the reasons are 
kept confidential. Most transplant centers will inform the recipient that the donor is not 
suitable on medical grounds, even when the actual reason may be different. This is done to 
protect the donor and to avoid any deterioration in the relationship with the recipient 
(Trotter J et al., 2007). The team must establish that there is no donor monetary compensation 
and no coercion to donate by family or others. The potential donor’s disclosure and consent 
process should be completely documented. 
4.3 Donor advocate 
In many transplant centers, a donor advocate evaluates the donor independent of the 
transplantation team. The advocate should not be in contact with the potential recipient and 
should not be influenced by the severity of the recipient’s illness. The donor advocate could 
be a social worker, psychiatrist, or physician. The primary role of the donor advocate is to 
protect and promote the interests and well-being of the donor, and to help the donor 
through the entire process. The advocate should not pre-empt the donor’s decision, since the 
donor continues to possess the ethical and legal right to decide to proceed with LDLT (Chen 
Y et al., 2003). The donor advocate should be able to answer the following questions. Is the 
donor adequately informed about the transplant procedure? Is consent truly informed? Is 
the donor vulnerable in any way to exploitation? Is the donor aware of alternative options 
for the recipient? Does the donor recognize the possibility of future health problems related 
to donation? (Trotter J 2000) 
4.4 Relationship to the recipient 
Reasons for donation are more understandable when there is a close bond between the pair. 
For genetically unrelated prospective living donors, questions must be tailored to the 
specific situation to fully understand why the individual wishes to donate. 
4.4.1 Live unrelated donation 
It has been well established that live genetically-unrelated emotionally-related donors 
such as spouses, partners or friends can be potential donors for LDLT. There are surgeons 
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against spousal donation advising that since a good percentage of marriages end in 
divorce there is no guarantee of a long-lasting loving relationship as a motive for such 
donation. Friends have been accepted reluctantly as potential donors, despite the fact that 
they might feel less pressure to donate compared to a family member (Terasaki P. et al., 
1997). 
4.4.2 Donation by strangers and good samaritan donors 
Occasionally, an unrelated (so-called “altruistic”) donor may volunteer to be assessed for 
LDLT, but such a practice is best avoided if possible. The intrinsic reasons for such 
unreserved altruism, especially in the adult-to-adult LDLT setting, are usually ill-defined 
prior to the surgery, and may only surface afterward, leading to serious unforeseen 
problems (Choudhry et al., 2003). The majority of transplant centers disapprove living 
donation between strangers, expressing doubts about their motivation and commitment to 
donation, their understanding of the potential risks and their psychological stability. 
Such donors may benefit from their act with increased self-esteem and may experience great 
satisfaction without being coerced by any sense of obligation. It has been proposed that in 
non-directed donation, the donor and recipient should remain anonymous to each other and 
probably meet only after the transplant, if they both agree. It has been suggested that true 
altruists do not need the name of those they help. Yet, the donors might want to see the 
results of their good deed, and the recipients might want to express their gratitude to the 
donor. It seems unethical to allow potential donors to specify particular characteristics of the 
recipient (e.g. sex, religion or race) (Levinsky N, 2000).  
4.5 Commercialization of organ donation 
It may be said that, living related donation involves a ‘highly artificial altruism’ according to 
which everyone is paid, including the transplant team as well as the recipient who gains an 
important benefit and only the donor is required to be altruistic. On the other hand, 
shortage of cadaveric organs has led to a worldwide black market for living-donor organs. 
Of course, it is unethical to sell human organs. A poor donor may be compelled by their 
financial status to donate, thus making the action non-voluntary. Yet, on the contrary, the 
donor may be choosing the best from a list of bad options, since it carries significantly less 
risk than working, for example, under harsh and dangerous conditions. Paid donors are, in 
their majority, poor and less educated, thus possibly unable to understand the risks 
involved (Choudhry et al., 2003).  
4.6 Paired-exchange programs 
A possible way to increase the live-donor pool is the paired exchange programs. In such 
programs, pairs of potential donors who are incompatible with their recipients donate 
eventually to each other’s recipient. Some have suggested that strict confidentiality should 
be maintained for each donor-recipient pair because there is a possibility of frustration, 
anger or resentment between the two pairs, in case one recipient does not have such a good 
outcome as the other. It is also suggested that both procedures should be performed 
simultaneously in order to avoid the possibility of one donor refusing after the other donor 
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procedure had already been performed (Park K et al, 1999). Psychological evaluation should 
be more meticulous to ensure that the donors are acting voluntarily. With the advances in 
immunosuppression and plasma-exchange techniques, such programs may be unnecessary, 
since ABO- incompatible transplants may be possible. 
4.7 Orphan graft 
The possibility of being unable to transplant a liver graft (orphan graft) into the intended 
recipient because of intraoperative death or other causes should be included in a prospective 
protocol at all institutions performing LDLT. Recommendations for handling an orphan 
liver graft include, (1) before donation, informed consent should be obtained from all donors 
indicating what the donor would want to have done with the orphan graft, (2) the sequence 
of steps in the operation should be structured to avoid removal of the donor graft until the 
recipient hepatectomy has been performed and the recipient’s survival is likely, and (3) the 
orphan graft is allocated according to preestablished institutional guidelines (Siegler J et al., 
2004). If the recipient dies intraoperatively and this possibility has not been covered in the 
preoperative consent discussion, the surgical team must obtain oral and written consent 
from the donor or the donor’s family to reallocate the organ. 
5. Evaluation and selection of the potential recipient 
5.1 Selection of the potential recipient 
Given the potential risks to the living donor, only recipients with a reasonably favorable 
post-transplant outcome should be considered for LDLT. Thus, before proceeding to work 
up any potential donor, the recipient candidate should first be deemed suitable for the 
LDLT operation both medically as well as surgically (Abdullah K et al, 2007). 
All potential LDLT recipients must first be listed for DDLT. This ensures the following, (1) 
the recipient is an appropriate candidate for liver transplant and avoids LDLT being done 
in futile situations (e.g., inoperable hepatocellular carcinoma), (2) should there be any 
post-LDLT complications including poor- or nonfunctioning graft, the recipient can be 
immediately upgraded to a top priority status to obtain a DDLT, and (3) third-party 
payers may require listing for DDLT before approving a patient for LDLT (Tan et al., 
2007). 
It has been suggested that a MELD score of 18 may be a reasonably good cutoff level 
above which LDLT is indicated, because a patient with a MELD score above 18 has a 
greater than 10% risk of 90-day mortality without transplantation; this exceeds the 1-year 
mortality after LDLT (10%). On the other hand, for patients with a MELD score below 17, 
the risk of transplant surgery is said to outweigh the risk of death from liver disease (Li C 
et al, 2010). 
Whether there is an upper limit for the MELD score above which LDLT may not be a viable 
option is unclear. Poorly decompensated patients have a comparatively poor prognosis and 
may not tolerate LDLT very well. It is thought that small grafts are unable to meet the needs 
of patients experiencing severe and prolonged illness. Some experts argue that a MELD 
score greater than 25 precludes LDLT, since a whole allograft, rather than a partial liver, is 
required to ensure adequate post-transplant recovery (Li C et al., 2010).  
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On the other hand, some of the patients with a low MELD score (below 18) may have other 
medically compelling reasons that prompt to consider LDLT (Li C et al., 2010; Trotter J et al., 
2005). These cases may include: 
1. Patients with HCC who may benefit from an expeditious LDLT before tumor 
progression occurs while on the waiting list (see later).  
2. Patients with a low MELD score that does not truly reflect their illness e.g. those with 
cholestatic liver diseases such as primary biliary cirrhosis or primary sclerosing 
cholangitis. These patients may have significant refractory symptoms or complications, 
e.g. severe pruritus, intractable ascites, infections, or hepatic encephalopathy. 
3. Patients with symptomatic benign hepatic masses, e.g. huge hemangioma, 
hemangioendothelioma, polycystic liver disease.  
4. Patients with metabolic disorders, e.g. familial amyloidosis, hyperoxaluria, tyrosinemia, 
and glycogen storage disease.  
5. Patients where LDLT can help prevent life-threatening complications, e.g. 
cholangiocarcinoma in primary sclerosing cholangitis. 
5.2 Evaluation of the potential recipient 
The evaluation of potential recipients for LDLT involves a multidisciplinary team approach 
which includes transplant surgeons, hepatologists, psychologists/psychiatrists, social 
workers, nurse coordinators, and other consultants (anesthesiologist, cardiologist, 
pulmonologist, infectious disease, neurologist, gynecologist, nutritionist, dentist, etc) 
(Abdullah K et al., 2005). Although the pretransplant workup varies with transplant centers, 
it should not differ from that of those accepted for DDLT. Most programs require a basic 
battery of laboratory tests, imaging studies, EKG, upper GI endoscopy and thorough 
evaluation of the general medical condition and fitness for major surgery (see Table 1).  
5.2.1 Psychosocial evaluation of the potential recipient 
The pretransplant period can be extremely stressful. Declining health, uncertainty about the 
possibility of LT, and inability to continue working and participating in daily activities all 
may increase the risk of depression and/or anxiety for the transplant candidate. Those 
patients who experience psychological distress prior to transplantation are likely to experience 
increased distress after transplantation, which may ultimately impact their recovery from 
transplantation (Walter M et al., 2002). Patients with chronic hepatitis C hepatitis have a 
greater incidence of depression and anxiety than patients with other forms of liver disease; 
thus, these patients in particular should be carefully screened and monitored. Patients who 
experience depression or anxiety are encouraged to seek psychiatric treatment prior to LT to 
improve their emotional and physical functioning. Some patients experience psychological 
distress or impairment that interferes with their health behavior to an extent that it may 
prevent them from adhering to medical directives. These patients should be required to 
pursue psychiatric services until their functioning is stable enough to be evaluated and 
satisfactorily listed for LT (Walter M et al., 2002). 
5.2.2 Social support 
Patients cannot and should not undergo stressful LT without considerable social support. 
Depending on the severity of the patient’s illness at the time of LT evaluation, many family 
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members and/or close friends may already have assumed care giving duties, including 
overseeing medication and dietary regimens and coordinating the patient’s medical 
appointments. Specifically, the caregiver’s relationship with the patient, current functioning, 
availability, and willingness to provide perioperative care should be assessed, as patients 
will rely heavily upon their caregivers during the perioperative period. 
 
Laboratory tests 
1. ABO blood grouping. 
2. Complete blood count, serum electrolytes, BUN, creatinine, liver biochemistry, 
alpha-fetoprotein and coagulation panel. 
3. Serology (hepatitis markers, RPR, HIV, CMV, EBV, etc). 
4. Stool and urine analysis and cultures. 
5. Others (serum alfa-1 antitrypsin, ferritin, ceruloplasmin, antinuclear antibody, 
antismooth muscle antibody etc.) 
Imaging studies 
1. Chest x-ray. 
2. Abdominal ultrasound to assess the patency of hepatic vasculature, presence of 
ascites, and to exclude focal lesions. 
3. Abdominal CT/MRI to exclude HCC, and to clarify abnormalities seen in ultrasound. 
EKG 
Endoscopy: Upper GI endoscopy to evaluate and treat varices. 
For selected patients 
1. Mammography, pap smear and pregnancy tests for female patients. 
2. Dental and dermatology evaluation.  
3. Cardiac stress test if EKG is abnormal.  
4. Coronary angiogram if cardiac stress test is positive. 
5. Carotid duplex. 
6. Pulmonary function tests and arterial blood gas. 
7. Bone scan and bone density. 
8. Liver biopsy. 
9. ERCP.  
10. Colonoscopy. 
11. PPD skin test. 
Table 1. list of investigations required for evaluation of a potential LDLT recipient 
5.2.3 Readiness for transplantation 
Certain patients may be in denial regarding the severity of their liver disease. It is important 
to ensure that patients possess a good understanding of the transplant process. When 
assessing readiness for transplantation, patients are reminded of the importance of continued 
adherence to all medical directives. 
5.3 Contraindications for recipient listing for LDLT 
Contraindications to LDLT are becoming fewer. Absolute contraindications for LDLT are 
similar to those for DDLT and include multisystem organ failure, severe and uncontrolled 
sepsis, irreversible brain damage, extrahepatic malignancy, advanced cardiopulmonary 
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disease, active substance abuse, and medical noncompliance. Common relative 
contraindications include thrombosis of multiple visceral veins, multiple significan 
abdominal surgeries, morbid obesity, uncontrolled diabetes, HIV, adverse psychosocial 
factors, and advanced age. Budd-Chiari syndrome and portal vein thrombosis are not 
usually deemed to be absolute contraindications (Trotter J et al., 2005).   
6. Controversial indication for LDLT 
6.1 Hepatitis C infection 
At present, patients with HCV should not be denied live donor transplants. Large number 
of studies has been published supporting differing views including that LDLT for patients 
with hepatitis C yields worse results, equivalent results, and even better results than those 
of DDLT. The majority of studies, however, have suggested the outcome is not different for 
HCV-positive recipients undergoing LDLT (Gallegos-Orozco J 2009). The benefits of LDLT 
in HCV-positive patients include: younger donors, less cold ischemia time, and the 
possibility of successfully treating patients with antiviral therapy prior to transplantation. It 
is not certain whether the regeneration of a partial liver graft, particularly in small-for-size 
grafts may stimulate and increase the rate of reactivation of the latent infection. Previous 
concerns about a higher frequency of cholestatic hepatitis or more aggressive fibrogenesis 
with live donors have not turned out to be true (Kuo A; Terrault NA 2009.). 
6.2 Hepatocellular carcinoma (HCC) 
Success in treating HCC with transplantation has been complicated by the supply and 
demand issues. LDLT was developed as a solution to this imbalance between cadaveric 
donor graft availability and the growing number of potential recipients. Changes in organ 
allocation systems giving priority to specific HCC patients have raised questions to the use 
of LDLT as a treatment for HCC. From an operative standpoint, the HCC patient is an ideal 
LDLT recipient, because the MELD priority points assigned to HCC patients mean that they 
have a much lower calculated MELD score. HCC patients generally have preserved liver 
function and less portal hypertension, and they are better able to tolerate implantation of a 
relatively undersized graft (Takada Y et al., 2010). 
6.2.1 Indications for LDLT for patients with HCC 
6.2.1.1 Long time on the waiting-list for DDLT 
A main indication for LDLT in HCC is when the patient will not likely receive a deceased 
donor organ in a timely fashion with the resulting potential for tumor progression to an 
untransplantable state. Therefore, in regions where cadaveric donation is limited by 
religious and cultural beliefs or there is a prolonged waiting time for deceased organs, the 
use of LDLT to curb tumor progression and increase survival is indicated. Even in areas 
where the waiting time is moderate, LDLT may still be valuable, if it can be determined 
that tumor progression is accelerated. Independent predictors of tumor progression may be 
useful to define aggressive tumors that are more sensitive to waiting list time. Thus, in 
those patients with large and multiple tumors, and those with high AFP levels, LDLT may 
still be indicated in those settings with short to moderate waiting time (Bhangui P et al., 
2011). 
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6.2.1.2 HCC exceeding the Milan criteria 
A second potential indication for LDLT in HCC patients is the presence of tumors exceeding 
the Milan Criteria. There is evidence to suggest, that Milan criteria may be too restrictive, 
and that there may be patients with potentially curable tumors that go untreated because of 
their exclusion from DDLT listing. The idea of using LDLT to transplant those patients with 
HCC exceeding the Milan Criteria requires a reasonable possibility of long-term survival 
(Shirabe K et al., 2011). 
6.2.2 Impact of LDLT on HCC recurrence 
Some centers have noted an increase in the recurrence of HCC when examined on a stage-
for-stage basis in those patients who have had their transplant waiting time shortened by 
using expanded donor options (LDLT, split liver transplants, domino liver transplants). In 
contrast, other centers have described no difference in recurrence rates between LDLT and 
cadaveric transplant for HCC. The explanations offered by the groups that report a higher 
rate of recurrence are: (1) the release of growth factors and cytokines that induce hepatic 
regeneration in LDLT. These factors have tumor-promoting effects (2) the biological 
aggressiveness of the tumor. Prolonged waiting time allows a tumor to declare its biological 
aggressiveness. Using LDLT to shorten the time on the waiting list may result in 
transplanting very aggressive tumors that have already metastasized on a microscopic level 
but are not yet apparent. A short waitlist time may prevent identification of these aggressive 
tumors, so that LDLT may result in transplanting those patients that are likely to have 
recurrent HCC. Preoperative microdissection genotyping of the HCC, with measurements of 
DCP levels, may identify HCC with a high certainty of recurrence and allow judicious use of 
LDLT minimizing recurrence attributed to “fast-tracking.” (Kaido T et al., 2011) 
6.2.3 Ethical concerns 
Because the donor safety is the paramount concern in LDLT, it is important to consider 
ethical issues related to LDLT specific to HCC. The potential risks and complications to the 
donor mean that LDLT should only take place when there is an acceptable survival. 
However, some will argue that survival outcomes for LDLT for HCC should be compared to 
nonsurgical/no-treatment outcomes rather than compared to outcomes from transplanting 
non-HCC patients (Mazzaferro V et al, 2008). 
LDLT is ethically justified in those cases where waiting time is disproportionately long and 
the prolonged waitlist increases the risk of the HCC progression to a nontransplantable state. 
The risk to the donor can be justified because acceptable survival results can be expected. 
On the other hand, when LDLT is performed for HCC that exceeds the Milan Criteria it is 
ethically less clear, because the LDLT is being done due the recipient’s exclusion from a 
possible cadaveric transplant. It is difficult to justify the potential risks to the donor in such a 
situation where the society prohibits a transplant because it is unlikely to be of benefit. As 
stated above, there is accumulating evidence, however, that slightly exceeding the Milan 
Criteria can still yield acceptable survival and for this situation LDLT may be ethically 
acceptable. Beyond this, there is poor survival, and it is not acceptable to expose the donor 
to the risks in this situation. Normally if a graft acutely fails, it requires an urgent 
retransplant (Shirabe K et al., 2011). If LDLT were used in a situation where a cadaveric  
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donor is contraindicated, such as exceeding the Milan Criteria, the urgent retransplant 
would require a cadaveric organ, even though the patient was originally contraindicated. In 
these situations, the patient should not be retransplanted (Takada Y et al., 2010). 
6.3 Acute liver failure 
Patients with fulminant hepatic failure (FHF) rarely recover spontaneously, and there is a 
limited interval between the onset and irreversible complications and death. Despite 
advances in medical management, including hemodiafiltration and plasma exchange, the 
survival rate of patients with FHF under these treatments is low. Liver transplantation is the 
only available effective treatment for this group of patients. Timely access to an organ is 
paramount, to ensure reversibility of the condition. Although the outcomes of LDLT are 
fairly acceptable despite severe general conditions and emergent transplant settings, the use 
of LDLT for patients with FHF is a matter of controversy and raises significant ethical issues. 
The major advantage of LDLT for FHF is the timely availability of a liver graft. This has 
beneficial effects on the neurological outcomes (Matsui Y et al., 2008).  
But LDLT also has major disadvantages. The donor needs to be selected in a timely fashion, 
under medical and social pressures. In addition, there is the possibility of acquiring an extra 
small graft, which cannot support the metabolic demand of a recipient. Some physicians 
have expressed concern that the expedited evaluation in the setting of acute liver failure 
potentially could preclude the potential donor from making a careful reasoned decision 
about donation. Because of these concerns, some centers have elected to exclude acute liver 
failure as an indication for LDLT (Rudow D et al, 2003). 
In countries where DD transplants are limited, LDLT is the only chance to rescue patients 
suffering from highly urgent conditions like FHF, with satisfactory overall patient and graft 
survival rates. On the other hand, in countries where DDLT is available, such patients are 
listed as high priority and thus have a good chance to receive a DDLT in a short time. 
However, even programs with good access to DDLT, LDLT should be kept as a viable 
option in emergency situations, when any wait increases the risk to the potential recipient.  
6.3.1 Ethical concerns 
The emergency nature of FHF could preclude the potential donor from making a careful 
decision about donation. The process of informed consent by the donor could also be 
influenced by coercion from family members or from the medical team. Autocoercion is also 
a strong possibility. In the context of extending elective LDLT to the more urgent situation 
of FHF, transplant programs must pay special attention to the autonomy of the potential 
donor and must ensure truly informed consent (Rudow D et al., 2003). 
7. Donor evaluation  
Donor evaluation consists of comprehensive examinations evaluating medical suitability for 
major surgery, psychological suitability, and liver-related suitability. The two fundamental 
purposes of the donor evaluation are to ensure (1) donor safety and (2) that the donor is able 
to yield a suitable graft for the recipient. Members of the evaluation team should include 
hepatologist, surgeon, psychologist, social worker, and transplant coordinator (Marcos A et 
al., 2000). 
www.intechopen.com
 
Liver Transplantation – Technical Issues and Complications 
 
14 
Guidelines for evaluating potential living liver donors are not standardized. There is a great 
deal of variability among individual centers regarding components of their living donor 
evaluation protocols. Variability exists in the performance of some diagnostic studies, such 
as liver biopsy, hepatic angiography, and cholangiography (Totter J et al., 2002). The most 
frequently used model is a process that involves phases that are progressively more invasive 
and expensive (see table 2). In principle, one should try to limit the number of invasive 
investigations and reserve them for the later part of the evaluation. In an effort to limit the 
cost, more expensive tests are generally performed later in the evaluation process (Abdullah 
K et al., 2007). Another advantage of such a process includes several opportunities for the 
donor candidate to re-evaluate and reaffirm the decision to donate. The entire process 
usually takes a period of 1 to 2 months. In emergent situations, it can be shortened to less 
than 24 hours.  
The initial phase is designed to determine that the potential donor meets all the appropriate 
inclusion criteria for donation: appropriate blood type, age, body size, and relationship to 
the recipient. The initial screening history may be performed by an experienced transplant 
coordinator, or the donor is asked to fill out an information sheet. Questions regarding age; 
height; weight; blood type (if known); past and current medical, surgical, or psychosocial 
problems (including a history of alcohol use); and current medication use are included in 
the questionnaire (Totter J et al., 2002). The lower limit of age for donation is determined by 
the ability to give legal consent. The potential donor must be between the ages of 18 and 55 
years. However, some extend the upper limit to 60 years. Most centers require that the 
potential donor should show a significant long-term relationship with the recipient. Body 
size compatibility between the donor and recipient is an important preliminary 
consideration in the donor evaluation. The potential donor should have an identical or 
compatible blood type and no significant medical problems. Surgical history is documented, 
along with current medications. Serum electrolyte levels, blood count, liver function tests, 
and hepatitis serological tests are performed. Relative contraindications for donor 
evaluation are discovered frequently in this phase and include, previous significant 
abdominal surgery, hypertension, hypercholesterolemia, and obesity (Chen Y et al., 2003).  
The next phase, involves a thorough history and physical examination to determine 
eligibility for the operation. Female potential donors of reproductive age should undergo a 
pregnancy test. The use of oral contraceptive pills or hormonal devices indicates 
perioperative deep vein thrombosis prophylaxis by subcutaneous heparin in addition to 
physical means. This phase involves evaluation of the donor liver. This can be subdivided 
into three components, which include assessment of the (1) hepatic parenchyma, (2) liver 
volume, and (3) vascular and biliary anatomy (Bradhagen D, et al., 2003). 
7.1 Evaluation of hepatic parenchyma 
The presence of chronic liver disease and steatosis could have potential implications for both 
the donor and recipient. This begins with liver biochemistry tests, including aspartate 
aminotransferase, alanine aminotransferase, bilirubin, alkaline phosphatase, albumin, and 
international normalized ratio (Chen Y et al., 2003). Blood tests to exclude chronic liver 
disease often are performed early in the course of the evaluation. These tests include serum 
transferrin saturation, ferritin, ceruloplasmin, alfa-1-antitrypsin phenotype, antinuclear 
antibody, smooth muscle antibody, antimitochondrial antibody, and hepatitis serological  
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Phase 1  
The potential donor should satisfy the following before proceeding to the next phases 
1. Clinical evaluation:  
• Age: between 18 and 55 years. 
• Identical or compatible blood type with recipient. 
• Body weight, height and Body mass index. 
• Absence of previous significant abdominal surgery and/or medical problems. 
• Significant long-term relationship with recipient. 
2. Normal liver function test results, serum electrolyte levels, complete blood count 
with differential cell count, and negative hepatitis B surface antigen and hepatitis C 
antibody results. 
3. Informed consent (for testing and surgery). 
 
Phase 2 
1. Complete and thorough medical history and physical examination. 
2. Laboratory tests: 
• Serology: hepatitis A, B and C (surface antigen, core antibody, surface antibody), 
rapid plasmin reagin, cytomegalovirus antibody (immunoglobulin G), Epstein-
Barr virus antibody (immunoglobulin G), antinuclear antibody, human 
immunodeficiency antibody, toxicology/substance abuse screen.  
• Serum ferritin, iron, transferrin, ceruloplasmin, alpha-1-antitrypsin, transferring, 
alpha fetoprotein, carcinoembryonic antigen. 
• Urinalysis. 
• Coagulation profile; protein C; antithrombin III; factor V, VII, and VIII. 
• C-reactive protein. 
• Thyroid function tests . 
• Pregnancy test for female donors. 
3. Imaging studies:  
• Chest X-ray.  
• Abdominal ultrasound scan. 
• CT scan and magnetic resonance imaging to assess the liver volume, the biliary 
system, and vascular anatomy. 
4. Electrocardiogram. 
 
Phase 3 
1. Psychological evaluation, and informed consent. 
2. Other tests or consultations to clarify any potential problems uncovered during 
evaluation: e.g., endoscopic retrograde cholangiopancreatography, hepatic angiogram, 
liver biopsy, echocardiogram, and stress echocardiogram (some centers routinely 
perform some or all of these tests as part of the donor evaluation). 
 
Step 4 
1. Planning of OR date and availability of intensive care unit facilities. 
2. Blood bank: autologous blood donation. 
3. Second informed consent (for blood and surgery). 
Table 2. Suggested protocol for living donor evaluation  
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tests (hepatitis B surface antigen and antibody, hepatitis B core antibody, and hepatitis C 
antibody). Donors with evidence of underlying chronic liver disease or a positive hepatitis C 
antibody or, hepatitis B surface antigen result are excluded from further consideration. 
There is no consensus on the use of donors who are alfa-1-antitrypsin phenotype MZ or 
hemochromatosis C282Y heterozygotes. (Bradhagen D, et al., 2003)  
7.1.1 Steatosis 
Hepatic steatosis can be characterized histologically as microvesicular or macrovesicular. In 
general, macrovesicular steatosis is regarded as a benign lesion and often is asymptomatic, 
whereas microvesicular steatosis often is more serious. Hepatic steatosis can adversely affect 
both of the recipient and the donor. Steatotic livers may not function well because they are 
more susceptible to injury from general anesthesia and ischemia-reperfusion. In addition, 
steatosis has been shown to increase cold ischemic injury and impair hepatic regeneration. 
Several studies have shown that the risk for primary allograft nonfunction increases with 
increasing severity of steatosis. Because steatosis reduces functional hepatic mass, some 
advocate subtracting the percentage of steatosis from the estimated liver mass before 
calculating the final mass of the hepatic allograft and remnant (Bradhagen D, et al., 2003). 
There is currently no agreed cutoff value on the percentage of steatosis that is safe for 
performance of LDLT. The maximal acceptable amount of steatosis in the donor liver varies 
among LDLT programs and ranges from 10% to 30%. Several studies have shown that livers 
from deceased donors with less than 30% steatosis can be transplanted with results similar 
to organs without fat. Additional studies are needed to better define the acceptable amount 
of steatosis in the donor liver that will ensure a safe and successful operation for both the 
donor and recipient. There are some data to suggest that steatosis identified on a 
predonation biopsy can be reversed with a program of dieting and exercise, and rebiopsy in 
this situation may show the potential donor to be suitable (Chen Y et al., 2003). 
7.1.1.1 Liver biochemistry tests  
Liver biochemistry tests are not sensitive or specific and may even show normal results in 
those with advanced hepatic fibrosis. Other methods, such as body topography and lipid 
levels, have shown a weak correlation with hepatic steatosis. Of all biochemical parameters, 
serum triglyceride level appears to have the strongest correlation.  
7.1.1.2 Anthropometric measures 
Waist-hip ratio seems to be a good predictor of steatosis. An increased waist-hip ratio, 
which is present more commonly in men, is associated with a greater risk for hepatic 
steatosis. Of all noninvasive methods for assessment of hepatic steatosis, body mass index 
(BMI) may have the greatest utility. Several studies have shown a correlation between 
hepatic steatosis and increasing BMI. In addition, obese patients are more likely to have 
comorbid conditions (hypertension, hypercholesterolemia, and diabetes), which could 
increase the risk for postoperative complications after donor hepatectomy. Studies from the 
general surgery literature, suggest an increased incidence of surgical complications such as 
bleeding and wound problems in obese individuals. Obesity is also a risk factor for 
underlying cardiovascular problems, which could lead to an increased chance for medical 
complications posttransplant. Because of these risk factors, most obese donors will not be 
www.intechopen.com
 
Living Donor Liver Transplantation 
 
17 
suitable donors. In general, obese individuals (BMI > 28 kg/m2) are unsuitable for donation. 
Certainly a BMI of > 35 would be a contraindication. Many centers exclude donors with  
BMI > 30, but others will selectively evaluate these donors and perform a liver biopsy to rule 
out the possibility of liver steatosis (Bradhagen D, et al., 2003). 
7.1.1.3 Abdominal imaging 
Ultrasound, CT, and MRI, may detect the presence of hepatic steatosis. Their sensitivity and 
specificity are technique and operator dependent and also may vary based on degree of 
steatosis. The imaging modalities are not able to quantify the amount of steatosis or 
distinguish between simple steatosis and steatohepatitis. Iwasaki and colleagues (2004) have 
demonstrated that liver-to-spleen CT alternation values ratios using noncontrast CT scan are 
useful to detect appreciable hepatic macrovesicular steatosis. Newer imaging modalities, 
such as dual-echo and gradient-echo MR sequences, may provide increasing accuracy for 
the detection and quantification of hepatic steatosis. At present, the available abdominal 
imaging studies do not appear to be sufficiently sensitive or specific to replace liver biopsy 
in most situations (Iwasaki et al, 2004) . 
7.1.1.4 Liver biopsy 
Liver biopsy is the gold standard for the assessment of hepatic parenchymal disease, 
including steatosis. In general, liver biopsy is a safe procedure with a low risk for serious 
complications. Liver biopsy also is useful in excluding occult chronic liver disease. The 
appropriate use of liver biopsy in the evaluation of living donor candidates is an area of 
continuing controversy (Bradhagen D, et al., 2003). The role of liver biopsy in the donor 
evaluation process varies greatly from center to center. Some centers perform liver biopsy 
on all potential donors, whereas others perform liver biopsy based only on clinical findings 
that suggest some degree of concern e.g., significant history of alcohol intake, BMI greater 
than 28 kg/m2, elevated serum ferritin level, presence of steatosis on imaging studies, and 
so on. Liver biopsy may be avoided is patients with a BMI less than 25 who do not have 
diabetes, hypertension, or a history of excess alcohol consumption. In addition, they also 
should have normal liver test results and lipid levels and undergo tests to exclude chronic 
liver disease and hepatic imaging studies. Liver biopsy results that would preclude donation 
include fibrosis, nonalcoholic steatohepatitis (NASH), steatosis > 30% and histologic 
abnormalities such as inflammatory changes (Nadalin S et al, 2005). 
7.2 Volumetric assessment 
Donor safety is of primary concern, and the smallest resection that provides adequate actual 
and functional mass for the recipient is selected. Determination of adequate hepatic mass is 
critical for successful outcomes for both donor and recipient. Height and weight of the 
donor and recipient pair can be useful in excluding a very small donor when the intended 
recipient is large, but is not accurate enough in most other situations. Volumetric assessment 
of the hepatic segments can be performed using either CT or MRI. In general, hepatic mass 
estimated by volumetric imaging correlates well with actual hepatic mass determined at the 
time of hepatectomy. It is helpful for the surgeon to work with the radiologist in making the 
planned line of liver transection and to provide the most accurate assessment of graft 
volume (Hill MJ, et al., 2009).  
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Two formulas are used to assess graft size adequacy: (1) graft-recipient body weight ratio 
(GRBWR) and (2) graft weight as a percentage of standard liver mass. There is an excellent 
linear correlation between the two, and either is acceptable. It probably is reasonable to 
correct the GRBWR for steatosis by subtracting the percentage of steatosis noted on liver 
biopsy from the functional hepatic mass (Hill MJ, et al., 2009). 
Resection should not exceed 70% of the total liver volume; that is, the donor should be left 
with at least 30% of the measured total liver volume. Liver failure has been reported 
postdonation, with at least one donor requiring an urgent liver transplant because of liver 
failure after donation. As a result, LDLT has limited applicability in large patients because of 
the inability to identify a suitable donor (Nadalin S et al, 2004). 
A GRBWR of 1% is approximately equal to 50% of standard liver mass. The consensus is 
that the GRBWR should be equal or greater than 0.8 % (equivalent to about 40 % of the 
standard liver volume). It should be stressed, however, that these values are based upon 
LDLT performed in noncritically ill patients. Patients with significant decompensation of 
chronic liver disease will have excessive metabolic demands and require the maximum liver 
volume available. On the other hand, some authorities ( Selzner et al, 2009) suggest that, 
patients with Child’s class A cirrhosis or those without portal hypertension could receive an 
allograft with a GRBWR greater than 0.6%. Marcos A (2000) summarized the issue of hepatic 
mass by stating, “Neither the minimum transplantable hepatic mass nor the optimal mass 
have been accurately determined. In all likelihood, these values are dependent on both 
donor- and recipient-specific characteristics and could never be determined with precision”. 
For physically large recipients greater than 100 kg, the likelihood of finding a donor 
physically large enough to yield a sufficiently large graft is small. For a pediatric recipient, 
the main issue is not usually whether the liver volume may be too small; rather the issue is 
whether it may be too large; this may lead to problems with closure of the abdomen in the 
recipient. Usually the GRBWR should not exceed 5%(Bradhagen D, et al., 2003). 
7.3 Donor liver anatomy 
Variations in vascular and biliary anatomy can be quite common. Preoperative knowledge 
of the anatomical variations is important for planning the operative procedure and for 
maximizing the chances of a safe and successful operation for both donor and recipient. 
Preoperative imaging studies include MR angiography and cholangiography, CT 
angiography, ERCP, and mesenteric angiography. The choice of the imaging modalities is 
dependent on institutional experience and expertise. Most centers have abandoned the use 
of invasive tests such as angiogram, and routinely use CT or MRI with 3-D reconstructions 
(Tsang Let al, 2008).  
Common arterial variations include replaced right and left hepatic arteries with and without 
the presence of proper, right, and left hepatic arteries. These variations are usually 
detectable by CT or MR angiography. A replaced left hepatic artery increases donor safety 
because the artery is away from the surgical field and less prone to injury during right 
hepatectomy (Takatsuki M et al,2006). A completely replaced right hepatic artery is a 
favorable situation for both donor and recipient. It is longer than a right hepatic artery, 
remote from the left liver arterial in-flow, and more amenable to dissection from 
surrounding tissue. The presence of both replaced and standard right hepatic arteries 
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introduces more complexity. Reconstruction before implantation is possible with a 
bifurcated recipient proper hepatic artery graft, or the arteries can be sewn separately to the 
recipient right and left hepatic arteries. Nevertheless, the presence of two arteries increases 
the risk for thrombosis. Occasionally, a right hepatic branch may arise from the left hepatic 
artery or a left hepatic branch may arise from the right hepatic artery; both situations may 
preclude donation (Sugawara Y, et al. 2003). 
The most common portal venous variation is separate right anterior and posterior portal 
venous trunks which may require reconstruction before implantation (most commonly with 
a bifurcated venous graft) or separate anastomoses during implantation to the recipient 
right and left portal veins. A sizable left portal branch arising from the right portal system or 
a right branch from the left system may preclude donation (Xu M, et al, 2008 ). 
Hepatic venous anatomy is also variable. Most commonly, there are two tributaries to the 
middle hepatic vein (MHV) within the anterior segments of the right liver, segments V and 
VIII. The need for reconstruction of these tributaries in the recipient remains controversial. 
Some centers routinely reconstruct both veins, others reconstruct them when large, and 
others never do (see later). Large caudate veins also are common. Most centers reimplant 
caudate veins larger than 0.5 cm. Intraoperative ultrasonography is helpful, as well (Radtke 
A et al., 2010).  
The biliary anatomy may be difficult to evaluate accurately preoperatively. Some centers 
routinely perform MRCP or ERCP as part of the evaluation process. The latter is an invasive 
test, whereas the former may not provide the degree of accuracy and clarity required to be 
of value. As a result many centers choose to perform an intraoperative cholangiogram, 
rather than preoperative biliary imaging. However, ongoing improvements in imaging 
modalities may soon allow for preoperative noninvasive imaging that is equivalent to the 
intraoperative cholangiogram with regards to its detail and clarity. The most common 
variations are multiple right hepatic ducts that require separate anastomoses in the 
recipient, but. Occasionally, a left duct arises from the right system, but these ducts usually 
are small and can be safely divided during right hepatectomy (Limanond P et al, 2004).  
7.4 Evaluation for thrombophilia 
Deep venous thrombosis with subsequent pulmonary embolism represents a serious 
postoperative complication to the living donor. Several cases of pulmonary embolism have 
been reported with at least one donor mortality due to this complication. Known risk factors 
for thromboembolic complications include obesity, use of oral hormone therapy, old age, 
smoking, positive family history, and an identified underlying procoagulation disorder. 
These risk factors should be addressed during the evaluation process, including screening 
tests to identify a procoagulation disorder. Tests include, protein C and S and alfa-1-
antitrypsin deficiency, checking for factor VIII elevation, evaluating for the presence of 
antiphospholipid or anticardiolipin antibodies, and screening for the factor V Leiden and 
prothrombin gene mutations (Ogawa H, et al., 2011). 
7.5 Psychosocial evaluation 
This part of the evaluation assesses the donor’s mental fitness and willingness to donate, 
ensuring that consent is obtained in a voluntary manner with the absence of coercion. A 
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trained transplant psychiatrist, psychologist, clinical social worker, and psychiatric nurse 
perform this psychological assessment. The professional(s) responsible for psychological 
assessment should be part of the transplant team and must be experienced in the assessment 
of liver transplant recipients, so that they understand the particular context and unique 
psychological demands of liver transplants (Walter M, et al, 2002). 
No strict guidelines exist for psychological assessment of prospective donor. However, most 
transplant centers have adopted formal psychological assessment as an integral part of their 
donor evaluation. There are several components to this part of the evaluation, but basically 
the following issues should be addressed: (1) mental, psychological, emotional, and social 
stability, (2) motivation for donation including a careful assessment to ensure that there is 
no coercion or inducement involved and competency to give informed consent, and (3) full 
understanding of, the donation process, the surgery involved, the potential complications, 
and the recovery involved (Walter M, et al, 2002). 
The presence of underlying mental illness, cognitive impairments, aberrant personality 
traits, or other factors that may interfere with the potential donor’s ability to make a 
reasoned decision may preclude donation. A history of anxiety, depression, or other 
concerns are discussed to determine whether donation could exacerbate underlying 
symptoms. Present and past behaviors are explored because they may be predictors to 
coping with potential donor outcomes. Donors must understand how donation could 
impact on their mental health (Noma et al., 2010). 
The clinical psychologist makes an independent recommendation as to whether the donor 
is suitable to undergo donation. Informed consent to proceed with the necessary tests and 
surgery is discussed in detail with the prospective donor. After all the donor candidate’s 
questions are answered to his or her satisfaction, written consent is obtained, and a copy of 
the consent form is given to the candidate to keep; this is separate from a second written 
informed consent, which is obtained prior to the LDLT surgery itself. Upon completion of 
this step, a decision regarding donor acceptability needs to be made by a multidisciplinary 
committee, which takes into consideration both the medical and ethical aspects of each 
case. 
8. Hepatitis B virus core antibody positive donors 
The presence of antibody to hepatitis B core antigen (anti-HBc) in the absence of hepatitis B 
surface antigen (HBsAg) signifies past exposure to hepatitis B virus (HBV) and may 
represent a state of resolved infection with immunity or recent clearance of HbsAg and yet 
persistent low-grade hepatitis activity. The use of live donors who are anti-HBc positive 
involves consideration of two factors: risk to the donor and potential risk of transmission to 
the recipient. With regard to the recipient, the issues are no different from those for a 
deceased donor who is core positive (Suehiro T et al., 2005). 
8.1 Risks to the recipient 
Experience with the use of anti-HBc-positive livers from deceased donors indicated that the 
risk of HBV reactivation varies with the recipient’s HBV serology status. A variety of terms 
such as de novo hepatitis B, recurrent hepatitis B, transmission of hepatitis B, or reactivation 
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of hepatitis B have been used to describe HBV infection in this setting. The presence of anti-
HBs in the recipient has been reported to protect against reactivation. Anti-HBc 
seropositivity has also been shown to be associated with a lower risk of HBV reactivation. 
On the other hand, the concomitant presence of anti-HBs in the donor’s serum does not offer 
any protective effect. Other factors as the Child-Pugh score and the type of 
immunosuppressive therapy, have been suggested to affect the rate of HBV reactivation 
through its effect on the host immune response (Munoz S, 2002).  
8.1.1 Strategies to minimize the risks to the recipient  
a. Matching: In DDLT. anti-HBc-positive liver graft from a deceased donor is usually 
allocated first to HBsAg-positive recipients who would in any case need prophylaxis 
against recurrence. Unfortunately, a matching policy has little role in the practice of 
LDLT. A living donor is evaluated for the possibility of donation to a specific recipient 
(Fontana R & Merion R, 2003). 
b. Prophylaxis against HBV reactivation: Strategies including hepatitis- B-immune 
globulin (HBIG) and/or lamivudine to prevent recurrent hepatitis B in HBsAg-negative 
recipients have been used (Suehiro T et al., 2005). 
8.2 Risks to the donor 
Theoretically, the potential problems in anti-HBc-positive donors include, (1) the underlying 
hepatitis infection may delay the recovery and regeneration of the liver remnant. (2) 
reactivation of integrated HBV virus in the postoperative period, (3) on the long-term, the 
occult hepatitis infection may progress to the development of cirrhosis or HCC and the 
previous hepatic resection for liver donation may compromise the prospects for appropriate 
treatment (Suehiro T et al., 2005). Whether the risk is significant in patients with 
biochemically and histologically normal liver is controversial. Transplant centers that accept 
living donors positive for anti-HBc are obliged to continue lifelong follow-up of these 
donors in order to assess these potential long-term sequels. 
8.3 Recommendations 
a. Detailed preoperative assessment is mandatory for both the donor and the recipient.  
b. Donors with ongoing chronic hepatitis and viremia as indicated by abnormal liver 
biochemistry and positive serum HBV DNA should be excluded.  
c. A routine preoperative liver biopsy is mandatory in the HB c antibody-positive donor. 
The presence of hepatic fibrosis would preclude donor hepatectomy. 
d. Donors seronegative for anti-HBs should receive HBV vaccination to protect against the 
risk of future HBV reactivation.  
e. For the HBsAg-positive recipients, there is no need for any adjustment to the 
appropriate prophylaxis against HBV recurrence.  
f. All HBsAg-negative recipients should receive prophylactic treatment with lamivudine 
alone or in combination with HBIG after transplantation.  
g. Both the donor and the recipient should receive regular and lifelong follow-up. Any 
episode of liver dysfunction should be investigated for HBV reactivation with 
serological and virological testing. (Suehiro T et al., 2005; Fontana R; Merion R, 2003) 
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9. Technical aspects of LDLT 
Timing of the donor procedure in relation to the recipient procedure is very important. 
Recipients with nonmalignant disorders are usually brought to the operating room after the 
anatomy in the donor has been assessed and found to be suitable for donation. Recipients 
with potentially malignant lesions should be explored through a relatively small right 
subcostal incision before the donor is anesthetized. If enlarged lymph nodes are found, 
biopsies are sent for frozen section (Henrik P et al., 2009; Polak W et al., 2009).  
9.1 Recipient hepatectomy  
A generous bilateral subcostal incision and upward midline extension is made. Native 
hepatectomy with caval flow preservation is performed in a standard fashion except for 
vascular and biliary management. Hilar dissection is made to free the right and left hepatic 
artery, the common hepatic duct, the right and left portal vein and its main trunk. The tissue 
around the common hepatic duct is preserved as far as possible in order to retain its blood 
supply (Soejima Y, et al., 2008). It is then divided close to the liver hilum so as to retain 
enough length for subsequent duct-to-duct anastomosis. The left and right portal veins must 
be free for the full length (Kim B et al., 2009). The portal vein is not divided until the liver 
graft is available. Then, the main portal vein is clamped and the right and left portal veins 
are divided close to the liver hilum. The hepatic veins are clamped and divided. The hepatic 
vein stump intended for venous outflow reconstruction is slit open to fashion a triangular 
venotomy opening that matches in size and shape with the hepatic vein opening of the liver 
graft (Henrik P et al., 2009; Polak W et al., 2009).  
9.2 Donor right hepatectomy 
9.2.1 Access 
Access is gained through a bilateral subcostal incision with upper midline extension. The 
ligamentum teres is ligated and divided, and the falciform ligament severed toward the 
suprahepatic vena cava to reveal the border between the RHV and the MHV. The right liver 
is then mobilized by dissection of the triangular ligament (Cipe G, et al., 2011). 
9.2.2 Intraoperative cholangiogram and Doppler ultrasound 
Cholecystectomy is performed and a tube for cholangiogram is inserted through the cystic 
duct. Cholangiogram can be postponed until the right hepatic duct is roughly dissected and 
marked with a clip. Intraoperative Doppler ultrasound is performed to map the position 
and direction of the MHV. The route of the MHV can be drawn on the anterior surface of the 
liver with electrocautery (Haberal M et al,2011).  
9.2.3 Mobilization 
The liver is rotated to expose the retrohepatic cava. Tiny, short hepatic veins are 
meticulously divided. Posterior hepatic veins with a diameter larger than 0.5 cm should be 
eventually reanastomosed to the cava of the recipient. The caval side of the vein is 
oversewn, and the venous stump is temporarily clipped. The IVC ligament just below the 
RHV usually contains vessels of significant caliber and should be oversewn after 
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transection. The RHV is fully exposed and encircled. The extent of the dissection of the 
retrohepatic-cava plane can be pictured as a longitudinal line drawn from the space between 
RHV and MHV to the midportion of the process of the caudate lobe. It usually corresponds 
to half to two thirds of the anterior surface of the IVC (Cipe G, et al., 2011). 
9.2.4 Hilar time 
Hilar dissection is started from the right side of the CBD. The RHA is identified first, 
followed by the portal vein. The RHA is dissected from its origin to the liver parenchyma. 
All large branches to segment IV should be spared. The posterior aspect of the RPV is then 
exposed with division of caudate lobe branches, if necessary. The RPV and RHA are 
temporarily clamped, with a noncrushing vascular clip, to visualize the demarcation line of 
the liver. The space between the right hepatic artery and the right hepatic duct should not be 
disrupted in order to preserve the blood supply of the latter (Soejima Y, et al., 2008).  
9.2.5 Parenchymal transection 
No matter whether CUSA, Water Jet Dissector, Monopolar and Bipolar Coagulator, Tissue 
Link or Staple Devices are used, the ultimate goal is to transect the parenchyma with the 
minimal blood loss possible, respecting the anatomical structures vital to the graft and to the 
donor. Individual preferences dictate the level of comfort in relying on the aforementioned 
devices (Cipe G, et al., 2011). Under a low central venous pressure and complete muscle 
relaxation, bleeding during liver transection would not be excessive. The plane of 
transection is dictated by the position of the MHV and whether it will be taken with the 
graft or not. (Humar A et al., 2006; Tanaka K et al., 2010; Belghiti J; R Kianmanesh 2003).  
The control and transection of the posterior plane above the vena cava can be facilitated by 
passing the umbilical tape between the hilar structures and the space between the RHV and 
MHV and pulling it by both ends ”the hanging maneuver”. In this way the liver is lifted 
upward and the resection is greatly facilitated.. To include the MHV in the graft during the 
hanging maneuver, the origin of the MHV is rounded and a tape is passed to the space 
between the LHV and MHV (Ogata S, 2007; Cipe G, et al., 2011).  
Some surgeons routinely give heparin before vascular clamping. The RHA, RPV, and RHV 
in sequence are separately clamped and divided, and the liver segment is immediately 
removed. The vascular stumps are oversewn with Prolene sutures. The donor side of the 
bile duct is closed after the graft is removed and the vascular stumps are oversewn (Henrik 
P et al., 2009; Polak W et al., 2009; Humar A et al., 2006).  
To shorten the cold ischemic time, the graft is not delivered until the recipient is almost ready for 
graft implantation. Precise communication between the two teams is vital in this regard (Cipe G, et 
al., 2011). 
9.2.6 Back-table procedure 
Once delivered, the graft is flushed with cold preservative solution either, University of 
Wisconsin (UW) (Via Span, Duramed Pharmaceuticals) or histidine-tryptophane-
ketoglutarate (HTK; Custodial, Odyssey Pharmaceuticals). The flushing is continued 
through the portal vein until the effluent from the hepatic vein is completely clear. This 
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usually requires 3 mL/g of liver weight (Henrik P et al., 2009; Polak W et al., 2009; Humar A 
et al., 2006; Tanaka K et al., 2010).  
Back-table reconstruction may be required as follows:  
a. Tributaries of the donor MHV may require extensions with an autologous vein grafts. 
b. The RHV may require a venoplasty using an autologous (portal) vein graft. If two right 
hepatic veins are present, and if they are not too far apart, they can be sewn together.  
c. If two portal vein orifices are present, and are not too far apart, they can be sewn 
together; alternatively, a venous Y-graft (of autologous portal vein branches from the 
recipient’s resected native liver) can be used.  
d. The orifices of the bile duct(s), if they are not too far apart, are sewn together; they can 
also be incised to create a larger anastomosis.  
e. The liver’s cut surface is inspected. Leaks identified during flushing are oversewn.  
9.3 Right liver implantation 
The liver graft is placed in a natural position. The implantation starts with the hepatic vein 
anastomosis performed in a triangular fashion using 5-0 Prolene. Attention should be paid to 
prevent inversion, especially of the posterior wall. There should be no tension on the suture 
(Polak W et al., 2009; Humar A et al., 2006; Tan H et al., 2007; Tanaka K et al., 2010).  
Portal vein anastomosis is completed using running 6-0 sutures to the RPV, portal bifurcation, 
or portal trunk of the recipient, depending on its diameter and distance. The running 
sutures are taken on the anterior wall from the medial to the lateral aspects of the recipient 
and donor portal veins. The suture is tied at the lateral side with incorporation of a “growth 
factor.” to prevent portal vein narrowing at the anastomotic site itself (Starzl TE et al., 1984; 
Xu MQ et al., 2008). 
The vascular clamp is removed from the recipient portal vein and the liver is reperfused. 
About 500 mL of blood are vented through the (untied) medial aspect of the vena cava 
anastomosis. The portal vein is clamped again, and the running suture of the medial aspect 
of the caval anastomosis is tied to the corner stitch. The clamps on the vena cava and the 
portal vein are now removed, and the liver graft is reperfused (Humar A et al., 2006; Tan H 
et al., 2007; Tanaka K et al., 2010 ). The surgeon assesses the quality of liver perfusion and 
stops any significant bleeding with suture ligation. Usually, the liver pinks up immediately. 
If the MHV was not included in the graft or if venous tributaries were not reconstructed, the 
medial aspects of segments 5 and 8 (right anterior or paramedian segments) may be dusky-
blue and are frequently swollen. The cut surface is assessed for bleeding and hemostasis is 
obtained (Henrik P et al., 2009; Polak W et al., 2009; Tan H 2007; Tanaka K et al., 2010).  
The arterial anastomosis is usually tedious because of its small size. The arterial anastomosis is 
usually performed end-to-end with 7-0 or 8-0 nonabsorbable sutures in interrupted fashion 
and the use of surgical loop magnification. Alternatively, an operating microscope can be 
used. After revascularization is complete, flow velocity and signal patterns are checked by 
Doppler ultrasonography (Henrik P et al., 2009; Polak W et al., 2009).  
Biliary reconstruction is technically demanding because of the small diameter and short 
length. More frequently, multiple small ducts are cut flush in the donor’s hilar plate are 
present. As a consequence, the incidence of technical complications, such as leaks and 
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strictures, is significantly higher with LDDT (vs. DDLT). The requirements are a tension-free 
anastomosis and preserving periductal connective tissue to maintain the bile ducts’ 
ascending axial vascular circulation (which originates from the RHA and the superior 
posterior pancreaticoduodenal artery). Biliary reconstruction is by direct anastomosis or 
hepaticojejunostomy (Kim B et al., 2009). Direct duct-to-duct anastomosis is now 
increasingly performed. In general, a duct-to-duct anastomosis is advantageous because it 
reduces operative time, represents a simpler biliary anastomosis, preserves physiologic 
bilioenteric and bowel continuity, preserves the physiologic sphincter mechanism with a 
decreased risk of ascending or reflux cholangitis, eliminates the need for bowel 
manipulation with a decreased risk of intraabdominal contamination and of postoperative 
ileus, results in earlier return of gastrointestinal function, allows easy radiologic access to 
the biliary tract. The decision to stent the biliary anastomosis is controversia (Kim B et al., 
2009). 
Possible options if more than one duct orifice is encountered (Haberal M et al., 2011): 
a. If the ducts are in close proximity or share a common wall, they can be joined together 
and only 1 anastomosis needs to be done.  
b. If the distance between the bile ducts is > 1 cm, two enterotomies may need to be made. 
c. Multiple orifices can be anastomosed to RHD, LHD, or the cystic duct of the recipient.  
d. If only one recipient bile duct is available for anastomosis, the remaining ducts require 
construction of a Roux-en-Y loop.  
e. Very small (< 1mm), distant biliary orifices are sometimes sacrificed and oversewn.  
9.4 Donor left hepatectomy 
Donor left hepatectomy consists of either full left, or left lateral hepatectomy depending on 
the relative donor–recipient size ratio(Humar A et al., 2006; Tanaka K et al., 2010).  
9.4.1 Exposure 
The abdomen is entered through a bilateral subcostal incision and a midline extension. After 
division of the round and falciform ligament, the LHV and MHV are exposed to their 
insertion to the IVC. The left triangular and coronary ligaments are excised to reveal the left 
surface of the LHV. Any accessory or replaced left hepatic artery from the left gastric artery 
is carefully preserved as the gastrohepatic ligament is divided (Humar A et al., 2006).  
9.4.2 Intraoperative cholangiography and Doppler ultrasound 
Intraoperative ultrasonography is performed to study the anatomy of the MHV and the 
LHV. Doppler study is also performed to locate the site of hepatic artery. Cholecystectomy 
is then performed and the cystic duct cannulated for operative cholangiography. The 
location of the proposed division of the left hepatic duct is marked by a large size metal clip 
(Henrik P et al., 2009; Polak W et al., 2009; Humar A et al., 2006).  
9.4.3 Mobilization 
The retrohepatic cava is defined after incising the overlying peritoneum along its lateral 
aspect, exposing the cava up to the LHV junction. Smaller draining veins are ligated or 
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clipped as the entire left lobe and caudate lobe are retracted to the LHV, MHV and RHV are 
isolated as they drain into the cava (Humar A et al., 2006; Tanaka K et al., 2010).  
9.4.4 Hilar time 
Hilar dissection is confined to the left side to free the LHA and LPV. Attention should be 
paid to the caudate branches of the LPV when moved back to its origin. The LPV is usually 
longer than the right, and a reasonable segment is isolated and looped. Some surgeons 
advocate preserving the caudate lobe and its dominant vein draining into the vena cava. If a 
large branch of the LHA arising from the left gastric artery is encountered, it must be 
preserved for subsequent reconstruction if needed (Soejima Y, et al., 2008).  
9.4.5 Parenchymal transection 
The Cantlie line is marked at the anterior surface of the liver by diathermy at a plane 
demarcated after temporary occlusion of the LHA and LPV. At the inferior surface of the 
liver, the division plane deviates to the left side of gallbladder fossa to meet the proposed 
dividing line of the LHD. The transection plane is angled to the left after identification of 
tributaries to the MHV. The LHD is cut sharply and the donor side is oversewn (Tan H et 
al., 2007 & Tanaka K et al., 2010). Further transection of the parenchyma is performed along 
the plane of the ligamentum venosus. Once parenchymal transection is complete, 
hemostasis and absence of bile leak are confirmed on both surfaces. The LHA, LPV, and 
LHV in sequence are separately clamped and divided, and the liver segment is immediately 
removed. Some surgeons routinely give heparin before vascular clamping. The vascular 
stumps are oversewn with Prolene sutures and the donor side of the bile duct is closed 
(Henrik P et al., 2009; Polak W et al., 2009).  
9.4.6 Left-sided liver implantation 
The implantation starts with the hepatic vein anastomosis performed in a triangular fashion 
using 5-0 Prolene. Attention should be paid to prevent inversion, especially of the posterior 
wall. There should be no tension on the suture. Depending on its length and diameter, the 
graft portal vein is anastomosed with the LPV, the portal bifurcation, or the portal trunk of 
the recipient, using running 6-0 sutures. At this point, the hepatic vein and portal vein are 
declamped. Arterial anastomosis is performed using interrupted 8-0 sutures . Sharp edges, 
adequate removal of surrounding tissue, and absence of tension or kinks in the anastomosis 
contribute to the success of this procedure. When two significant arteries are present within 
the graft, a good back flow in the second one after the reperfusion of the major one can be a 
good reason to ligate the second one. After revascularization is complete, flow velocity and 
signal patterns are checked by Doppler ultrasonography. Biliary reconstruction is by duct-
to-duct anastomosis or hepaticojejunostomy. Previously, hepatico-jejunostomy was thought 
to be the only reconstruction method for left-liver graft. Recently, more and more surgeons 
perform duct-to-duct anastomosis (Kim B et al., 2009).  
The liver graft is fixed by suturing the falciform ligament to the anterior abdominal wall to 
prevent rotation into the right subphrenic cavity. The latter may lead to graft congestion (as 
a result of MHV kinking) or poor vascular inflow (as a result of folding of the portal vein) 
and ultimately graft failure (Henrik P et al., 2009; Humar A et al., 2006).  
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10. The middle hepatic vein controversy 
The construction of an optimal venous outflow determines the outcome of LDLT. The 
routine anastomosis of the accessory inferior hepatic veins with a diameter larger than 0.5 
cm was accepted by almost all centers. However, there are no defined standards for the 
reconstruction of MHV or its tributaries (Chan SC et al, 2011). 
The MHV is responsible for the drainage segment 4 together with variable part of the 
anterior sector of the right liver (segments 5 and 8) in the great majority of the cases. 
Transection of the drainage territory of the MHV at the time of procurement leads to venous 
congestion of “marginal zones” in both graft and donor remnant (Radtke A et al., 2010).  
Poor venous outflow has been associated with increased sinusoidal pressure, disruption of 
sinusoidal epithelium, hepatic artery thrombosis, impaired liver regeneration, and dismal 
outcome. Such physiologic harm can be particularly detrimental in recipients with relatively 
small grafts and significant portal hypertension, in whom an underlying SFSS situation can 
turn into graft failure or at least lead to severe biliary and/or vascular complications. A 
triangular interrelationship between inflow, outflow, and GRBW ratio has been proposed to 
determine the fate of the graft (Humar A et al., 2006; Tan H et al., 2007).  
When the MHV is not taken with the graft, a variable portion of the anterior sector of the 
right liver remains congested. The relief of the congestion may occur either through 
intraparenchymal communication between the venous outflow of the anterior sector and 
the posterior sector drained by the RHV or by reversal of flow in the anterior branch of 
the portal vein into the posterior branch. The percentage of the congested portion relative 
to the overall volume of the graft, the GRBWR, the presence and the degree of portal 
hypertension, and the compliance of the liver determine the magnitude of graft 
malfunction after transplantation. If the functional mass of the right-lobe graft is adequate 
without the MHV (high GRWR), some degree of congestion may be tolerated early 
posttransplant, until the graft has regenerated or the anterior sector drainage is rerouted 
(Chan SC et al, 2011). 
10.1 Available options for the surgical management of the MHV 
(1) Exclusion of the MHV from the graft: The rationale is that not all right grafts present 
with congestion after reperfusion, and simple RHV anastomosis is sufficient in many cases. 
Obviously, if venous drainage from segments 5 and 8 is predominately via the RHV, 
including the MHV with the right-lobe graft is unnecessary. With the donor MHV clamped 
and reversal of flow in the anterior branch of the portal vein detected by Doppler, the 
temporary occlusion of the right hepatic artery will determine the portion of right liver 
affected by congestion (Chan SC et al, 2011). 
(2) Inclusion of the MHV with the right-lobe graft: This guarantees the most complete 
drainage of the anterior sector of the right graft. Contraindications are a small predicted 
residual liver volume (< 30%) in the donor as this may pose the donor at a higher risk of 
postoperative complications because the regeneration of segment 4 is stunned by the lack of 
adequate venous drainage (Radtke A et al., 2010).  
(3) Inclusion of the distal part of the MHV with the right-lobe graft (leaving the proximal 
remnant in the donor): This technique preserves large segment 4a venous tributaries into the 
www.intechopen.com
 
Liver Transplantation – Technical Issues and Complications 
 
28 
MHV in its most proximal portion. Inclusion of the distal MHV improves segment V 
drainage but not that of segment VIII (Chan SC et al, 2011). 
(4) Anastomosing the major tributaries draining the anterior sector of the right liver into the 
MHV to the vena cava leaving the MHV with the donor rest liver. Doppler waveform 
characteristics may identify tributaries that could benefit from separate anastomosis. Reversed 
flow in the MHV tributaries may indicate that reconstruction is not required. Reconstructing 
MHV tributaries according to diameter (> 5 mm) has also been recommended. The 
tributaries from segments 5 and 8 are anastomosed to venous conduits of various origins 
that serve as jump grafts. This has been accomplished with the donor inferior mesenteric 
vein, iliac vein, ovarian vein, cryopreserved iliac vein, recipient saphenous vein, umbilical 
vein, LPV, superficial femoral vein, and internal jugular vein. Reconstruction of 
interposition grafts is, preferably, done on the back table; it can also be done after restoration 
of portal flow, in order to first assess the degree of venous congestion. 
Reconstruction of these branches with interposition grafts results in a more complex 
operation, longer operating time, and longer warm ischemia time. Also, a relatively long 
segment of interposition graft makes it more prone to thrombosis (Radtke A et al., 2010). 
Whether one technical approach is sounder than the other is probably not possible to decide. 
Thus, individualized planning is mandatory for the optimal outcome of both donors and 
recipients in the setting of the high degree of variability of MHV, RHV, and IHV drainage. A 
selective approach based on GRBWR, greater or less than 1; graft/recipient standard liver, 
greater or less than 50%; and size of the MHV tributaries, greater or less than 5 mm in 
diameter; is used by the some groups to decide whether the graft will be harvested with or 
without the middle hepatic vein (Chan SC et al, 2011). 
11. Double liver transplant 
If the donor has a large right lobe (> 70% of total liver volume), the remaining left lobe will 
be small (< 30% of total liver volume) and thus will threaten donor safety. An alternative is 
to simultaneously transplant two small liver grafts (left lobe or left lateral segment) from 
two different donors; that is, a double or dual-graft transplant, to solve graft-size 
insufficiency and provide donor safety. The recipient and two donor operations are started 
simultaneously. The first graft is orthotopically positioned in the original left position. The 
second graft is heterotopically positioned to the right-upper-quadrant fossa, rotating it 180°, 
so that the graft’s hilar structures are at the same level as the recipient’s right hilar structures 
(Lu Q, et al., 2010).  
12. Retransplantation  
The only therapeutic option for failing hepatic allograft is a liver retransplant. The most 
common causes are chronic rejection, chronic cholangitis, and vascular complications, small 
for size graft and primary nonfunction. In Re-LDLTs, ethical problems and the timing of the 
retransplant are controversial. Furthermore, availability of LDLT and DDLT for 
retransplants differs in each country or region. Donor selection for Re-LDLTs is difficult. 
The probability of retransplants (with either DDLT or LDLT) is low because of the lack of 
donors. Thus, serious posttransplant complications after LDLT often lead to death, with no 
chance of a retransplant. During the procedure, surgeons encounter difficulty in dissecting 
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surrounding tissues and identifying the important vessels due to the relatively small size 
and short length of vessels in LDLT grafts (Lerner S et al., 2005).  
13. Recipient outcomes and complications of LDLT 
The spectrum of posttransplant complications is not different for LDLT versus DDLT. 
However, the incidence of biliary, and vascular complications may be more common and 
severe in nature than in DDLT. In addition, new problems such as small-for-size syndrome 
have been introduced (Soin A et al., 2010 ).  
13.1 Hepatic artery complications 
13.1.1 Hepatic artery thrombosis (HAT) 
Risk Factors include, recipients body weight < 10 kg or age < 3 years, reconstructing arteries 
with diameters < 3 mm, ABO incompatibility, excessive intraoperative fresh frozen plasma 
transfusion, and elevated hematocrite levels. Doppler ultrasonography has high sensitivity 
for the diagnosis of HAT. By performing serial examinations at frequent intervals during the 
first 1 to 2 weeks posttransplant, HAT can be detected before it becomes clinically obvious. 
Early diagnosis permits immediate thrombectomy and revascularization before the patient 
deteriorates. If there is suspicion for HAT, one can choose to delineate the anatomy with 
angiography or proceed urgent re-exploration. Angiography offers nonoperative method to 
diagnose and potentially treat with balloon angioplasty (Steinbrück K, et al., 2011). 
Management depends on the timing and the clinical condition . Early HAT, once diagnosed 
by ultrasound, the patient is immediately taken to the operating room. The anastomosis is 
taken down. The vessel is cleared of all clot, inspected for intimal injury, and assessed for 
adequate inflow. If good inflow is present, a primary anastomosis is attempted. If adequate 
inflow is not provided, an arterial conduit is anastomosed to the aorta. Postoperatively, the 
patient is closely watched with frequent Doppler. Systemic heparinization is used according 
to coagulation parameters (Steinbrück K, et al., 2011).  
If there is a delay in the diagnosis, or if ultrasound is questionable, selective arteriography 
may be employed to diagnose the site of thrombosis and to begin therapeutic thrombolysis. 
Decisions on retransplantation are made based on the clinical condition, patency of the 
vessels, and appearance of late complications as biliary stricture (Steinbrück K et al., 2011). 
Late HAT is often asymptomatic because of the development of a rich collateral network. 
Attempts at operative revision should not be undertaken, as a large majority survive with 
normal allograft function, and any operative procedure carries the risk of destroying the 
graft-sustaining collaterals. Significant late allograft dysfunction needs careful monitoring 
for septic complications, biloma and cholangitis. Attempts at graft salvage in this population 
are universally unsuccessful (Henrik P et al., 2009; Polak W et al., 2009).  
13.1.2 Hepatic Artery Stenosis (HAS) 
HAS, although usually asymptomatic, will eventually progress to HAT. Frequently, patients 
develop biliary strictures and bile leaks. HAS may be detected on surveillance Doppler. 
Dampened waveforms with decreased resistive indices (RI) and slow peak velocities 
suggest HAS. Stenosis should be suspected when the RI is <0.5 or the systolic ascending  
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time (SAT) is >10 msec. The diagnosis should be confirmed by angiography. If diagnosed in 
the immediate postoperative period, planned exploration and revision of the arterial 
anastomosis should be undertaken. Although conventional treatment is either surgical 
repair or a retransplant, percutaneous transluminal angioplasty (PTA) or stent placement is 
becoming predominant (Polak W et al., 2009; Humar A et al., 2006; Tanaka K et al., 2010). 
13.2 Biliary complications 
Biliary complications remain the most common cause of postoperative morbidity and the 
most challenging complications in LDLT recipients, and occasionally graft loss and death. 
Risk factors include, small size or multiple bile duct anastomoses, delayed arterial 
revascularization, HAT, extensive periductal dissection and biliary leaks from the cut-
surface of liver tissue., cytomegalovirus infection, and rejection (Yuan Y & Gotoh M, 2010). 
13.2.1 Biliary leaks 
The sources of biliary leaks could be from (1) The cut surface of the liver, (2) The site of the 
biliary anastomosis, (3) The site of the intestinal anastomosis, and (4) The exit site of a T tube 
(or other types of external stents). Anastomotic leaks are caused either by ischemic necrosis 
of the end of the bile duct or by a technically unsatisfactory anastomosis. Leaks can manifest 
as sudden onset of biliary drainage from the abdominal drain, or they may present by 
intraabdominal collection, referred to as “biloma”. Biloma can be detected by 
ultrasonography or CT scan before the recipient becomes symptomatic (Khalaf H et al., 
2011).  
Leaks from the cut-surface can be managed expectantly as long as it is adequately drained. 
Leaks from the anastomosis also can be successfully managed with nonsurgical treatment if 
they are small and localized. Stenting with percutaneous transhepatic cholangiography 
(PTC) or ERCP at the anastomotic site can resolve minor leaks. If the anastomosis is 
seriously disrupted, surgical revision is the safest approach (Kohler S et al. 2009).  
For bilomas, percutaneous drainage is performed. Once the patient is stabilized, ERCP or 
PTC is performed, and a stent is placed to bypass the flow of bile through the leak. If 
excessive leak is diagnosed in the immediate post operative period, operative exploration, 
drainage, and revision of the anastomosis may be warranted (Khalaf H et al., 2011).  
13.2.2 Biliary strictures 
Risk factors include, CMV infection, hepatic artery complications, ABO incompatible 
transplantation, and prior anastomotic leak. The patient may present with asymptomatic 
elevation of cholestatic liver enzymes or may present with manifestations of cholangitis: 
fever, jaundice abdominal pain. Ultrasound scan is the initial imaging technique, however, 
ductal dilatation is often late. Direct cholangiogram is the gold-standard for diagnosing 
biliary strictures. Any patient with biliary stenosis, especially with multiple strictures, 
should be evaluated for HAT (Kohler S et al. 2009). Early strictures are often amenable to 
endoscopic or transhepatic intervention with good long-term results. Operative treatment is 
indicated for complications of percutaneous therapies and intractable strictures. Patients 
with strictures associated with HAT should continue to undergo percutaneous treatment. 
Operative exploration should be avoided, as it disrupts the arterial collaterals supplying the  
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graft. Evaluation for retransplantation should occur if the strictures affect graft function, 
associated with bilomas and frequent bouts of cholangitis (Yuan Y and Gotoh M, 2010). 
13.3 Portal vein thrombosis (PVT) 
Risk factors include, native PVT, the use of interposition grafts, extensive collaterals, 
portosystemic shunts and splenectomy. The patient may present with ascites, elevated LFTs, 
and splenomegaly, and gastrointestinal hemorrhage. Diagnosis is made with Doppler and 
confirmed by venography. Early PVT is treated with surgical thrombectomy and revision of 
the anastomosis. Late PVT may require surgical shunting to decompress the portal system 
as treatment of the complications of portal hypertension (Kyoden Y, et al., 2008). 
13.4 Hepatic venous outflow block (HVOB) 
Risk factors include, technical causes, graft rotation and kinking of the anastomosis and 
graft regeneration with subsequent rotation. HVOB is occasionally diagnosed during 
transplant surgery on the basis of swelling and congestion of the graft. The diagnosis is 
confirmed if intraoperative ultrasonography detects a flat waveform in the hepatic vein. 
Postoperatively, the clinical presentation includes ascites, elevated liver function test results, 
splenomegaly, variceal bleeding, lower-extremity edema, and kidney dysfunction. A 
persistent monophasic wave pattern from the hepatic vein on Doppler ultrasonography 
suggests substantial stenosis. Subsequent angiography with direct contrast can confirm the 
diagnosis; the pressure gradient across the stenosis is typically > 3 to 10 mm Hg. 
Management is by percutaneous balloon venoplasty. Multiple procedures are often 
required. Stent placement may be required for cases that do not respond to simple 
dilatation. In severe cases, HVOB may cause graft dysfunction or failure, requiring a 
retransplantion (Ikeda O, et al., 2010). 
13.5 Abdominal compartment syndrome 
Causes include, oversized allograft as in adult to pediatric LDLT, closure with considerable 
intra-abdominal tension, and intestinal edema due to prolonged portal vein clamping. The 
patient presents with, respiratory compromise, renal insufficiency, hemodynamic instability, 
and allograft thrombosis because of excessive pressure and positional kinking of the graft.  
13.6 The ‘small for size’ liver graft syndrome (SFSS) 
SFSS is a clinical syndrome, which occurs in the presence of a reduced mass of liver 
insufficient to maintain normal liver function. It is characterized by a combination of early 
postoperative progressive cholestasis, persistent portal hypertension, ascites, kidney failure, 
and coagulopathy. Microscopic features include cholestasis with hepatocyte ballooning, 
vacuolar degeneration, sinusoidal disruption, steatosis, and centrilobular necrosis. SFSS 
reduces the graft survival rate and increases the mortality rate (Selvaggi G& Tzakis A, 2009). 
13.6.1 Pathophysiology 
A partial liver graft transplanted into an adult recipient is, by definition, a small-for-size 
graft. Such a graft is, however, well tolerated when it is not under a critical size. The 
pathogenesis of the syndrome is primarily tied to graft volume, but three other factors have 
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been proved to contribute to its occurrence, (1) functional liver mass (graft volume, steatosis, 
donor age), (2) recipient status and the severity of hepatic disease at the time of the 
transplant, and (3) graft perfusion (portal hypertension, impaired venous outflow, and 
immune-mediated cellular infiltration) (Dahm F et al., 2005). 
Reduced intrahepatic vascular bed with higher portal flow per gram of remnant liver results 
in increased portal pressure. Following reperfusion, portal vein flow (PVF) is inversely 
related to graft size, while hepatic artery flow is reduced proportionately to graft size. 
Impaired HA flow is results from increased PVF. Enhanced PVF induces shear stress and 
endothelial injury with progressive alterations of hepatic microcirculation. Shear stress is 
responsible for up-and-down regulation of vasoregulatory genes, alteration of tissue repair 
mechanisms, and imbalance of intracellular homeostasis. Liver regeneration may be 
hindered by increased hepatic portal resistance (Selvaggi G & Tzakis A, 2009).  
13.6.2 Prevention and treatment  
Different strategies have been proposed (Selvaggi G& Tzakis A, 2009; Dahm F et al., 2005): 
a. Pharmacologic approach aiming to reduce the portal pressure. 
b. Ischemic preconditioning of the liver to protect the parenchyma against prolonged 
ischemic periods. 
c. Extracorporeal liver support to enhance of liver regeneration. 
d. Surgical techniques to control high PVF and PVP after graft reperfusion: 
• Splenic artery ligation (SAL) with or without splenectomy. 
• Meso-caval shunt with downstream ligation of the superior mesenteric vein.  
• Graded porto-caval shunt, portal vein band, or porto-mesenteric disconnection. 
e. Retransplantation  
14. Donor outcomes and complications 
14.1 Recovery of the liver function after donor hepatectomy 
Early aminotransferase elevation is common after donor hepatectomy. Liver enzymes peak 
early, in the first 48 hours, whereas bilirubin tends to peak later, approximately 
postoperative day 3. Exaggerated enzyme leak in the absence of synthetic dysfunction 
suggests focal ischemia, which can occur for example with a devascularized segment 4 
following lateral segmentectomy. Prolonged or exaggerated cholestasis in the absence of a 
biliary complication suggests ischemia or a small residual volume. Unusual clinical patterns 
of liver function should be investigated with ultrasound scanning, duplex sonography 
and/or computed tomography (Dindo D et al., 2004). 
14.2 Donor complications 
In worldwide reports donor morbidity ranged between 0% and 67%, depending on the 
individual definition and recognition of morbidity. Donor morbidity is influenced by 
variables including center experience, extent and technique of hepatic resection, anatomic 
factors, and general health of the donor (Fernandes R, et al., 2010). The lack of a standardized 
assessment of perioperative complications is a limitation to the analysis of donor-related 
morbidity. A universally accepted classification system for living donor complications 
would be ideal. This would allow accurate comparisons and help establish trends in the 
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assessment of morbidity. In this regard, modifications of the Clavien scale for LDLT is 
gaining acceptance as the standard for reporting surgical morbidity. This system consists of 
four grades of severity (Clavien P et al. 1994; Dindo D et al., 2004). 
Grade I consists of complications that are not life threatening and do not result in any 
significant morbidity, such as superficial wound infections or transient bile leaks.  
Grade II includes complications that have the potential to be life threatening or those 
requiring drug therapy or <1 foreign blood unit, but does not require therapeutic invasive 
therapy and does not result in residual disability. An example is any infectious sequelae 
requiring antimicrobial treatment, postoperative bleeding without requiring relaparotomy 
and local controlled deep venous thrombosis without thrombembolic complications. 
Grade III complications are potentially life threatening, requiring invasive intervention, 
blood transfusions and/or leads to readmission into the ICU, but does not lead to residual 
disability. For example, postoperative bleeding requiring relaparotomy, bile leak requiring 
endoscopic or surgical procedures, deep wound infections requiring relaparotomy or 
interventional drainage and deep venous thrombosis with pulmonary embolism 
Grade IV includes any complication with residual or lasting disability or that leads to death. 
Examples include liver failure requiring liver transplantation.  
The majority of donor morbidity are Grades I and II, with Grade III complications less 
frequent. The most commonly reported complications are listed in Table 3. 
 
Medical complications 
1. Transient cholestasis  
2. Pulmonary complications: atelectasis, pneumonia, pleural effusion, and pneumothorax 
3. Hypophosphatemia  
4. Thrombocytopenia 
5. Psychiatric complications 
6. Urinary infection  
General Surgical complications 
1. Wound infection 
2. Postoperative bleeding 
3. Deep vein thrombosis and pulmonary embolism 
4. Incisional hernia  
5. Nerve palsy  
6. Bowel obstruction, ileus  
Hepatectomy related complications 
1. Aborted donation  
2. Portal vein thrombosis 
3. Biliary tract complications: leaks, biloma, strictures 
4. Liver failure, hepatic encephalopathy  
Table 3. The most commonly reported complications in living donors 
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14.2.1 Biliary complications 
Biliary leaks after left lateral segment donation range from 5% to 10%, with a higher rate (up 
to 13%) in right hepatectomy. The source of leaks are typically the cut surface of the liver, 
however, the stump of the bile duct could be the source. Most leaks are diagnosed in the 
early postoperative period during the initial hospitalization by assessment of postoperative 
drain fluid, though late leaks are also reported. For most cases, observation and simple 
external drainage of the otherwise asymptomatic patient will be sufficient to avoid sepsis 
until the leak spontaneously resolves. More severe leaks require an interventional radiology 
procedure, endoscopic biliary, or reoperation (Yuan Y & Gotoh M. 2010). 
Strictures are reported less commonly but will more likely require invasive intervention. 
Bile duct strictures result from injury to the right, left or common hepatic duct during 
hepatectomy. Bile duct strictures may increase the lifetime risk of the donor for developing 
secondary biliary cirrhosis (Yuan Y, & Gotoh M. 2010). 
14.2.2 Acute liver failure 
Early postoperative acute liver failure suggests a vascular event like portal vein or arterial 
thrombosis, or acute outflow obstruction. Although acute vascular events can be reversible 
with immediate intervention (usually surgical), the patient should be listed for 
transplantation because survival in acute liver failure is directly related to the timing of liver 
replacement before the development of multiorgan failure or neurological injury (Fernandes 
R, et al, 2010; Dindo D et al., 2004).  
14.2.3 Small-for-size remnant liver 
Liver failure in the absence of an early technical complication like arterial or portal venous 
thrombosis is likely to be caused by a small-for-size remnant liver. Remnant liver volumes 
less than 30%, especially if there is underlying steatosis have been associated with 
prolonged cholestasis, portal hypertension, and normal or near enzymes and synthetic 
function after hepatectomy (“small-for size-syndrome”), especially in the presence of 
moderate steatosis. Outcome data for small for size syndrome in donors are sparse. The 
presence of a concomitant complication like bile leak, infection, or bleeding may exacerbate 
the poor recovery in a small-for-size liver. Treatment of small-for-size syndrome is 
supportive care and avoidance of further injury to the remnant (Fernandes R et al., 2010). 
15. Living donor mortality  
Liver donation puts the donor at risk of medical and surgical complications and even death. 
Unfortunately, the actual risk of death after a donor hepatectomy is unknown, because of 
the absence of sufficient database to allow an accurate determination of this infrequent but 
devastating outcome. When death occurs in a healthy donor, there are exceptional 
consequences. A donor death will have a devastating effect not only on the families and 
friends of the donor and recipient but also on all the clinical staff involved in the procedure. 
The impact of death may spread to other potential donors and recipients, and brings 
negative publicity and potential economic damage to the transplant center (Trotter J, 2006; 
Hashikura Y et al., 2009).  
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Placing a healthy individual at risk of death for a procedure that does not directly benefit 
him or her needs to be balanced by the autonomy and the psychological benefit to the 
donor. If a donor gives informed consent and if the transplant team is prepared to undertake 
the procedure, where is the problem?(Akabayashi A et al., 2004; B Ringe & R Strong 2008) 
The estimated donor mortality rate is 0.5%. The causes of death include, pulmonary 
embolism, pulmonary infection due to uncommon pathogen, emphysematous gastritis, liver 
failure due to congenital lipodystrophy and non-alcoholic steatohepatitis, acute pancreatitis 
and cerebral hemorrhage. Donor suicide was also reported. The exact number of live liver 
donor mortality in the world is not available because no central reporting agency exists. 
Current estimates of donor death rates are derived from either survey data or single-center 
reports. The use of survey data (in which transplant programs are retrospectively queried 
regarding clinical outcomes) is inexact because of incomplete follow-up of all donor 
outcomes and bias toward reporting favorable results (Trotter, J. et al., 2006). Single-center 
reports are likely to provide more complete follow-up data but, may be biased and are 
limited by the relatively small numbers of cases. In the absence of a definitive means to 
record all donor deaths, the medical literature has included reports of deaths that in many 
cases are based on verbal communications, circular references, or frankly unsubstantiated 
outcomes. As a result, the actual number of donor deaths after LDLT is difficult to ascertain 
and is a subject of considerable speculation (Trotter J 2006; Akabayashi A et al., 2004) 
The first donor death reported in the world was related to a fatal pulmonary embolus 
occurring in an adult-to-child living donor liver transplantation and was reported in the 
literature in detail. The first reported death in the United States was related to anaphylaxis 
secondary to medication, also in a left lateral segment donor (Trotter J 2006 B Ringe &R 
Strong 2008). The first death reported from Asia occurred in Kyoto, Japan (Akabayashi A et 
al., 2004). The donor was a mother in her late forties donated the right lobe of her liver to her 
daughter with biliary atresia. The mother fell into liver failure and underwent an 
unsuccessful domino liver transplant from a donor with a metabolic disease. Histological 
examination of the donor liver revealed that she had nonalcoholic steatohepatitis (NASH).  
In Egypt, the number of LDLT procedures performed annually has increased rapidly in the 
past few years (Abdeldayem H et al., 2008 & 2009). In January, 2010, the number of LDLT 
procedures performed in Egypt topped out to more than one thousand procedures, done in 
11 centers. The case number 1000 had been performed at the National Liver Institute in 
Menoufeyia. Although the author is aware of at least 6 deaths among living donors in 
Egypt. the reported deaths were only two. While one case has apparently been fully 
reported in the literature, the second death was reported in brief in the proceedings of the 
international congress of organ transplantation, in November 2008 (Abdeldayem H et al., 
2008 ) The first death was a 45 year-old male who donated the right hepatic lobe to his 
brother and died of sepsis from bile leak 1 month after donation (El-Meteini M et al., 2010). 
The second donor was a 22 year-old male who donated his right lobe to his father, suffered 
from massive intraoperative bleeding from the stump of the portal vein and died of 
multisystem organ failure after 10 days (Abdeldayem H et al., 2009).  
15.1 What is the acceptable risk of mortality to the donor? 
The main issue is what the acceptable risk of mortality to the donor is and, who should 
determine if this risk is acceptable? ? Donors may be willing to accept high rates of mortality 
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if the life of a loved one is in jeopardy. But what mortality rate is acceptable when the donor 
understands the risks and coercion has been excluded? There has to be a balance between 
the risk incurred by the donor and what is acceptable to the recipient, the society, and. the 
medical community (Trotter J 2006; Hashikura Y et al., 2009; Akabayashi A et al., 2004;  
B Ringe & R Strong 2008; Abdeldayem H et al., 2008 & 2010, Abdullah K et al., 2005, 2007) 
16. Transparency and LDLT 
Many, including the author, believe that, the true death, and complication rates among both 
the donors and the recipients in LDLT are underestimated. As clinicians involved in the 
evaluation of LDLT, we strive to present accurate information on the risks of the procedure. 
Because of the discrepancy found between published and unpublished data, the dilemma 
between reporting rumor vs. reporting facts currently prevails. The reluctance to publish 
any death or serious complication, although understandable in a fraught medicolegal 
environment, is not good for patient care or the procedure of LDLT itself. Potential liver 
transplant donors and recipients are best served by accurate information derived from 
genuine transparency. To maintain truly informed consent, it is imperative that all serious 
complications and deaths be reported. Transplant centers must be fully aware of their own 
responsibility: being honest to themselves and their patients. Secrecy is unacceptable, as it leads to 
gossip and speculation by others. If the mortality of this surgery is truly as high as reported 
by some editorialists, a very different message needs to be conveyed to the patients (Ringe & 
R Strong 2008; Abdeldayem H et al., 2008, 2009 &2010; Abdullah K et al., 2005& 2007). To be 
“transparent” or not to be? That’s the question!, … and the answer is clear. 
17. Conclusions 
LDLT will continue to play an important role for many patients who have no chance of 
receiving an organ from a deceased donor in timely fashion. This procedure demands 
technical expertise in both hepatobiliary surgery and whole-liver transplantation and hard 
work of multidisciplinary medical team. Every step requires attention and should be 
planned and performed meticulously. The main drawback with LDLT is the potential for 
donor morbidity and mortality. In order to promote living donation, absolute transparency 
about the risks and benefits of this procedure is mandatory.  
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